Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00074902" target="_blank" >RIV/00216224:14110/14:00074902 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/14:00061574

Result on the web

<a href="http://dx.doi.org/10.1182/blood-2013-08-521468" target="_blank" >http://dx.doi.org/10.1182/blood-2013-08-521468</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2013-08-521468" target="_blank" >10.1182/blood-2013-08-521468</a>

Result language

angličtina

Original language name

Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma

Original language description

Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide andto both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, &gt;/-3 prior treatment lines and low platelet counts correlating with short survival.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Blood

ISSN

0006-4971

e-ISSN

—

Volume of the periodical

123

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

7

Pages from-to

985-991

UT code for WoS article

000335836700013

EID of the result in the Scopus database

—